Logo

Catalyst's Firdapse (amifampridine) Receives FDA's Approval for Lambert-Eaton Myasthenic Syndrome

Share this

Catalyst's Firdapse (amifampridine) Receives FDA's Approval for Lambert-Eaton Myasthenic Syndrome


Shots:

  • The approval is based on two clinical trial results assessing Firdapse vs PBO in 64 patients with Lambert-Eaton Myasthenic Syndrome
  • The study measured Quantitative Myasthenia Gravis score (assessing muscle weakness) and demonstrated overall impression having effective results vs PBO
  • Firdapse (amifampridine) is an EU approved drug in Dec 2009- indicated for symptomatic treatment of adults with Lambert-Eaton Myasthenic Syndrome (LEMS) and has also received FDA’s PT- BT & ODD

Ref: Catalyst | Image: Twitter

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions